Abstract. Ewing's sarcoma (ES) is the second most common type of pediatric bone tumor, and is associated with a poor prognosis. Picropodophyllin (PPP), a novel selective inhibitor of insulin-like growth factor-1 receptor (IGF-1R), is able to strongly inhibit various types of cancers. However, the effect of IGF-1R on ES remains unclear. Following treatment with various concentrations of PPP for various times, cell viability was determined using an MTT assay. In addition, cell proliferation and apoptosis was investigated separately by bromodeoxyuridine staining and flow cytometry, respectively. The PPP-associated signaling pathway was also investigated. The results of the present study suggested that PPP inhibited cell proliferation and viability of A673 and SK-ES-1 human Ewing's sarcoma cells in a dose-and time-dependent manner. In addition, cell apoptosis rates were increased following treatment with PPP. Further investigation of the underlying mechanism revealed that PPP inhibited Akt phosphorylation. Fumonisin B1, an Akt-specific activator, reversed the inhibitory effects of PPP on cell growth. Furthermore, the results suggested that PPP decreased the expression levels of IGF-1R, a common activator of Akt signaling. PPP inhibited the growth of human Ewing's sarcoma cells by targeting the IGF-1R/Akt signaling pathway. Therefore, PPP may prove useful in the development of an effective strategy for the treatment of Ewing's sarcoma.
Introduction
Ewing's sarcoma (ES) is the second most common type of primary bone and soft malignant tumor, often occurs in children and adolescents, and is characterized by a pathognomonic chromosomal translocation known as t(11;22) (q24;q12) or t(21;22) (q22;q12) (1, 2) . Despite rapid advances in modern biomedicinal therapy, the 5-year survival rate of patients with ES has only reached 50-60% (3, 4) . Numerous studies have focused on investigating the underlying mechanism of ES, as well as therapeutic targets for patients with ES; however, the process of ES carcinogenesis remains largely unknown (5) (6) (7) (8) (9) . Therefore, developing an effective therapeutic strategy for the treatment of ES is critical for young patients.
Insulin-like growth factor 1 receptor (IGF-1R) represents an important therapeutic target in the pathogenesis of ES cells, and is regarded to be an effective biological therapy for ES (10) (11) (12) . A previous study reported that mutations in IGF-1R may induce apoptosis and inhibit tumorigenesis, as well as enhance chemosensitivity in ES cells (13) . Previous studies involving the inhibition of IGF-1R to regulate cell proliferation and apoptosis were also conducted (14, 15) . Increasing evidence suggests that the IGF-1R inhibitor NVP-AEW541 may possess the ability to enhance cell apoptosis, inhibit proliferation or arrest the cell cycle in ES (16, 17) . Therefore, identifying more effective inhibitors of IGF-1R may prove to be advantageous in the prevention of ES.
Picropodophyllin (PPP), an epimer of podophyllotoxin, may be a novel selective inhibitor of IGF-1R. PPP strongly inhibits cell growth in various types of cancer, including lymphoma, asopharyngeal carcinoma and colorectal carcinoma (18) (19) (20) (21) . Although PPP induces apoptosis in cultured IGF-1R-positive tumor cells, the mechanism underlying these effects remains to be elucidated (22) . In addition, its effect on ES and the underlying mechanism also remain to be clarified. In the present study, the effects of PPP on the proliferation and apoptosis of ES cell lines was investigated, along with the associated signaling pathway. Cell proliferation analysis. A bromodeoxyuridine (BrdU) Cell Staining kit (Invitrogen Life Technologies) was used to investigate the effects of PPP on ES cell proliferation, according to the manufacturer's instructions. Briefly, the cells were seeded in 96-well plates (5x10 3 cells/well) for 24 h, and exposed to various concentrations of PPP for a further 48 h. The cells were then fixed with 10 µl BrdU for 5 h, and the medium (RMPI-1640 or DMEM) was discarded prior to the addition of 100 µl/well fixing/denaturing solution (Beyotime Institute of Biotechnology, Nantong, China), incubated at room temperature for 15 min. The solution was then removed and 100 µl/well prepared detection antibody solution (mouse anti-human BrdU monoclonal antibody) was added and incubated for 1 h at room temperature. The plates were then washed three times with phosphate-buffered saline (PBS), followed by the addition of 100 µl/well horseradish peroxidase (HRP)-conjugated secondary antibody solution, incubated for 30 min at room temperature. The plates were further washed three times with washing buffer, and 100 µl 3,3',5,5'-tetramethylbenzidine substrate was added, and incubated for 30 min at room temperature. The quantity of BrdU incorporated into the cells was determined at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Statistical analysis. The results are expressed as the mean ± standard deviation of at least three independent experiments. Statistical analysis was conducted using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). The statistical significance of the differences between the control and drug-treated groups were evaluated using an unpaired Student's t-test. P<0.05 was considered to indicated a statistically significant result.
Materials and methods

Cells
Results
PPP inhibits cell viability in a dose-and time-dependent manner.
Cell viability evaluation is one of the most important steps in the quality control process for therapeutic drug use (23) .
To investigate the effects of PPP on ES, an MTT assay was first used to assess the influence of PPP on the cell growth of the A673 and SK-ES-1 ES cell lines. As shown in Fig. 1A , PPP inhibited A673 and SK-ES-1 cell viability in a dose-dependent manner, and the half maximal inhibitory concentration (IC 50 ) values for the A673 and SK-ES-1 cell lines were 0.42 and 0.48 µM, respectively. Further analysis determined that PPP exhibited time-dependent inhibitory effects on A673 and SK-ES-1 cell viability. As shown in Fig. 1B , the percentage of A673 and SK-ES-1 cell viability declined significantly at 24 h, and the rates of cell viability were 49 and 52%, respectively, as compared with the control (P<0.05). These results suggest that PPP inhibits cell viability in a dose-and time-dependent manner.
Effects of PPP on cell proliferation. To evaluate the effects of PPP on ES cell proliferation, a BrdU cell staining kit was used. As shown in Fig. 2A , PPP was able to inhibit >50% of A673 cells at an value IC 50 of 0.42 µM. Although the effect of PPP on the SK-ES-1 cells was more marked than that on the A673 cells, cell viability still decreased by 44% in the A673 cells. These results suggest that PPP is able to inhibit ES cell survival.
PPP treatment induces ES cell apoptosis.
To further evaluate the effect of PPP on cell apoptosis, Annexin V/PI double staining was performed on the A673 and SK-ES-1 cells. The 
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SK-ES-1 cell apoptotic rates were significantly increased from 10.1 (control) to 38.5% (PPP-treated) (Fig. 2B ). The apoptotic rates induced by PPP are shown in Fig. 2C . The apoptotic rates in the A673 cells were significantly increased from 11.2% (control) to 40.8% (PPP-treated) following treatment with 0.42 µM PPP. These data demonstrated the effect of PPP on cell apoptosis in the A673 and SK-ES-1 cells.
PPP blocks ES cell growth through Akt signaling.
The Akt signaling pathway has an important role in cell progression, including proliferation and apoptosis. The activation of Akt improves the survival of ES cell lines (24) . To explore the mechanism underlying the effects of PPP on cell growth, the effects of PPP on Akt expression were detected in the A673 and SK-ES-1 cell lines. As shown in Fig. 3A and B, the total Akt levels remained unchanged, whereas the phosphorylation levels of Akt markedly decreased in the two cell lines. Therefore, PPP may inhibit ES cell growth via Akt signaling. To further verify this hypothesis, FB1, a specific activator of Akt, was used for subsequent study. Following pre-treatment with FB1, the viability of the A673 and SK-ES-1 cells was significantly increased. The viability of the A673 cells increased from 42.8 to 63.5%, following the addition of 20 µg/ml FB1. In addition, PPP-inhibited cell viability in the SK-ES-1 cells increased from 44 to 53, 60 and 70.5%, respectively, following treatment with various doses of FB1 (Fig. 3C) . Conversely, PPP-induced cell apoptosis was decreased from 42.55 to 20% (40 µg/ml FB1-treated groups) in the A673 cells, following treatment with FB1. Furthermore, apoptotic rates in the SK-ES-1 cells also decreased from 38.55 (PPP-treated) to 17.5% (40 µg/ml FB1-treated; Fig. 3D ). These results suggest that PPP markedly inhibits A673 and SK-ES-1 cell growth by blocking Akt signaling.
Effects of PPP on IGF-1R activation. IGF-1R is overexpressed in various tumors, including breast tumors, prostate tumors and myeloma (25) . In addition, IGF-1R has an important role in the prevention of apoptosis by inducing the Akt signaling transduction cascade (26) . To further investigate the PPP-regulated Akt signaling pathway in ES, the expression levels of IGF-1R were analyzed. Total IGF-1R expression levels in the A673 cells decreased by ~35% compared with untreated cells, whereas SK-ES-1 cells exhibited a 40% decrease in IGF-1R expression (Fig. 4) . Similarly, the phosphorylation levels of IGF-1R decreased by >50%, as compared with those of the control cells in the two cell lines. The A673 cells exhibited a 59% decrease in the phosphorylation levels of IGF-1R, and the SK-ES-1 cells a 50.5% decrease, as compared with the control group. As an inhibitor of IGF-1R, PPP significantly reduced the expression and phosphorylation levels of IGF-1R. These results suggest that PPP regulates ES cell growth via the IGF-1R/Akt signaling pathway.
Discussion
ES is a relatively rare type of malignancy predominantly occurring between the ages of four and 25 (27, 28) . The aim of current research is to acquire a greater understanding of the biological pathogenesis of ES, and to identify an effective drug for the treatment of ES (29) . Previous studies demonstrated that PPP inhibits numerous types of cancers, including osteosarcoma and human multiple myeloma (30, 31) ; however, no research has been performed to date on ES. To the best of our knowledge, the present study is the first to investigate the function of PPP in ES. The results of the present study demonstrated that PPP induces proliferation inhibition and apoptotic enhancement in human ES cell lines. Therefore, PPP may be effective in the inhibition of ES, and merits further investigation. Numerous molecular studies have demonstrated that the Akt signal transduction cascade usually participates in ES cell progression, cell apoptosis, cell proliferation and drug susceptibility (32) (33) (34) . As an IFG-1R inhibitor, PPP was found to have Akt inhibitory effects in neuroblastoma cell lines (35) . Furthermore, the efficacy of PPP against multiple myeloma has also been demonstrated (31) . To further investigate the mechanism underlying the cell growth inhibitory effects of PPP, the present study investigated the Akt signaling pathway in ES. The results indicated that PPP induced downregulation of p-Akt expression by ~50%. The inhibitory effect of PPP on p-Akt was recovered following treatment with an Akt-specific activator, FB1. These results demonstrated that PPP was indeed able to inhibit human ES survival by blocking the Akt signaling pathway.
Recently, IGF signaling has become a potential target for novel anticancer agents (36, 37) . IGF-1R is an activator of the Akt signaling pathway. The IGF-1R-mediated Akt signaling pathway exhibited anticancer effects in various types of cancer (38, 39) . Baumgarten et al (40) suggested that IGF-1R signaling may be required for Akt activation. Previous studies have also demonstrated the association between IFG-1R and Akt (41, 42) . In the present study, PPP appeared to block IGF-1R phosphorylation. Consequently, it was hypothesized that PPP may inhibit ES growth by inhibiting the IGF-1R-Akt signaling pathway.
In conclusion, the present study demonstrated the effectiveness of PPP in human ES. The inhibition of cell survival, as well as the effective induction of apoptosis, led to further investigation of the underlying mechanism. The IGF-1R/Akt signaling pathway was shown to involve the PPP-induced survival in ES cells. Therefore, the application of PPP may provide a novel therapeutic strategy for the treatment of ES.
